Suchbegriffe: HYPERPARATHYROIDISM, PRIMARY - COMPLICATIONS , . Treffer: 2
Verheyen, N; Meinitzer, A; Grübler, MR; Ablasser, K; Kolesnik, E; Fahrleitner-Pammer, A; Belyavskiy, E; Trummer, C; Schwetz, V; Pieske-Kraigher, E; Voelkl, J; Alesutan, I; Catena, C; Sechi, LA; Brussee, H; Lewinski, DV; März, W; Pieske, B; Pilz, S; Tomaschitz, A
Low-grade inflammation and tryptophan-kynurenine pathway activation are associated with adverse cardiac remodeling in primary hyperparathyroidism: the EPATH trial.
Clin Chem Lab Med. 2017; 55(7):1034-1042
Doi: 10.1515/cclm-2016-1159
Web of Science
PubMed
FullText
FullText_MUG
Wetzel, J; Pilz, S; Grübler, MR; Fahrleitner-Pammer, A; Dimai, HP; von Lewinski, D; Kolesnik, E; Perl, S; Trummer, C; Schwetz, V; Meinitzer, A; Belyavskiy, E; Völkl, J; Catena, C; Brandenburg, V; März, W; Pieske, B; Brussee, H; Tomaschitz, A; Verheyen, ND
Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial.
J Clin Hypertens (Greenwich). 2017; 19(11):1173-1180
Doi: 10.1111/jch.13064
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG